AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2023
Nov 1, 2023
34983_dirs_2023-11-01_548041af-4dc4-4c1b-8edf-26d5f8a727ce.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2023-10-26
Reporting Person: Carle Vanessa (Secretary)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-10-26 | Stock Options | $1.15 | A | 12500 | Acquired | 2028-10-26 | Common Shares (12500) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| common shares | 67 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warrants | $36 | 2024-11-13 | Common Shares (67) | 67 | Direct |
| Stock Options | $3 | 2026-04-26 | Common Shares (12500) | 12567 | Direct |
| Stock Options | $3 | 2026-06-08 | Common Shares (5000) | 17567 | Direct |
| Stock Options | $3 | 2026-09-01 | Common Shares (10000) | 27567 | Direct |
| Stock Options | $2.91 | 2027-08-29 | Common Shares (12500) | 40067 | Direct |
Footnotes
F1: Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
F2: Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
F3: Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19